Tag Archive for: Pharma

Neuraxpharm reports another year of sustained growth and international expansion

/in

CNS specialist continues growth strategy across Europe and beyond, optimizing commercial efficiency and maintaining strong focus on innovation Barcelona, Spain and Düsseldorf, Germany – 14 November 2024 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, marked the sixth anniversary since its rebranding as Neuraxpharm […]

Read more

Optimum’s hot topic: How do you turn a 10-person biotech into a $1.1 billion company sale in the space of seven years?

/in

During the BIO-Europe conference in Stockholm, Optimum co-hosted a special reception featuring a fireside chat with Renée Aguiar-Lucander, former CEO of Calliditas, who led the Swedish company since 2017 until recently – taking it from small biotech to its $1.1 billion acquisition. Here, we tell the story of her remarkable seven-year journey with the firm.  […]

Read more

Poolbeg Pharma plc to present POLB 001 pre-clinical study data at the 66th American Society of Hematology (ASH) Annual Meeting

/in

POLB 001 Reduces Cytokine Release Syndrome (CRS) in an in vivo animal model Positive results reinforce POLB 001’s potential in the prevention and treatment of cancer immunotherapy-induced CRS ASH is the world’s premier conference focussing on haematological malignancies 6 November 2024 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development […]

Read more

This week’s hot topic: Why Pharma will have to play the long game on Alzheimer’s drugs

/in

By Stephen Adams, Optimum Strategic Communications Few people expected England and Wales’s drugs spending watchdog, the National Institute for Health and Care Excellence (“NICE”), to approve Eli Lilly’s new dementia drug donanemab for use on the NHS last week.  At a reputed annual cost of at least £60,000 a year, including the care bill, it […]

Read more